Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer

被引：54

作者：

Regan, Meredith M. ^{[1
,2
,3
]}

Price, Karen N. ^{[1
,4
]}

Giobbie-Hurder, Anita ^{[1
]}

Thuerlimann, Beat ^{[5
,6
]}

Gelber, Richard D. ^{[1
,2
,3
,4
]}

机构：

[1] Dana Farber Canc Inst, Dept Biostat & Computat Biol, IBCSG, Ctr Stat, Boston, MA 02215 USA

[2] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA

[3] Harvard Univ, Sch Med, Boston, MA 02115 USA

[4] Frontier Sci & Technol Res Fdn Inc, Boston, MA 02215 USA

[5] Kantonsspital, Breast Ctr, CH-9007 St Gallen, Switzerland

[6] Swiss Grp Clin Canc Res SAKK, CH-3008 Bern, Switzerland

来源：

BREAST CANCER RESEARCH | 2011年 / 13卷 / 03期

关键词：

PREDICTIVE-VALUE; ANASTROZOLE; SURVIVAL;

D O I：

10.1186/bcr2837

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The Breast International Group (BIG) 1-98 study is a four-arm trial comparing 5 years of monotherapy with tamoxifen or with letrozole or with sequences of 2 years of one followed by 3 years of the other for postmenopausal women with endocrine-responsive early invasive breast cancer. From 1998 to 2003, BIG 1-98 enrolled 8,010 women. The enhanced design of the trial enabled two complementary analyses of efficacy and safety. Collection of tumor specimens further enabled treatment comparisons based on tumor biology. Reports of BIG 1-98 should be interpreted in relation to each individual patient as she weighs the costs and benefits of available treatments. ClinicalTrials.gov ID: NCT00004205.

引用

页数：16

共 32 条

[1] Switching to anastrozole after tamoxifen improves survival in postmenopausal women with breast cancer [J].

Boccardo, F. .

NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (02) :76-77

[2]

Burstein HJ, 2010, J CLIN ONCOL, V28, P3784, DOI [10.1200/JCO.2009.26.3756, 10.1200/JOP.000082]

[3] Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer:: Update of study BIG 1-98 [J].

Coates, Alan S. ;

Keshaviah, Aparna ;

Thuerlimann, Beat ;

Mouridsen, Henning ;

Mauriac, Louis ;

Forbes, John F. ;

Paridaens, Robert ;

Castiglione-Gertsch, Monica ;

Gelber, Richard D. ;

Colleoni, Marco ;

Lang, Istvan ;

Del Mastro, Lucia ;

Smith, Ian ;

Chirgwin, Jacquie ;

Nogaret, Jean-Marie ;

Pienkowski, Tadeusz ;

Wardley, Andrew ;

Jakobsen, Erik H. ;

Price, Karen N. ;

Goldhirsch, Aron .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) :486-492

[4] Analyses Adjusting for Selective Crossover Show Improved Overall Survival With Adjuvant Letrozole Compared With Tamoxifen in the BIG 1-98 Study [J].

Colleoni, Marco ;

Giobbie-Hurder, Anita ;

Regan, Meredith M. ;

Thuerlimann, Beat ;

Mouridsen, Henning ;

Mauriac, Louis ;

Forbes, John F. ;

Paridaens, Robert ;

Lang, Istvan ;

Smith, Ian ;

Chirgwin, Jacquie ;

Pienkowski, Tadeusz ;

Wardley, Andrew ;

Price, Karen N. ;

Gelber, Richard D. ;

Coates, Alan S. ;

Goldhirsch, Aron .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (09) :1117-1124

[5] Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial [J].

Coombes, R. C. ;

Kilburn, L. S. ;

Snowdon, C. F. ;

Paridaens, R. ;

Coleman, R. E. ;

Jones, S. E. ;

Jassem, J. ;

Van de Velde, C. J. H. ;

Delozier, T. ;

Alvarez, I. ;

Del Mastro, L. ;

Ortmann, O. ;

Diedrich, K. ;

Coates, A. S. ;

Bajetta, E. ;

Holmberg, S. B. ;

Dodwell, D. ;

Mickiewicz, E. ;

Andersen, J. ;

Lonning, P. E. ;

Cocconi, G. ;

Forbes, J. ;

Castiglione, M. ;

Stuart, N. ;

Stewart, A. ;

Fallowfield, L. J. ;

Bertelli, G. ;

Hall, E. ;

Bogle, R. G. ;

Carpentieri, M. ;

Colajori, E. ;

Subar, M. ;

Ireland, E. ;

Bliss, J. M. .

LANCET, 2007, 369 (9561) :559-570

[6] Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer:: The BIG 1-98 trial [J].

Crivellari, Diana ;

Sun, Zhuoxin ;

Coates, Alan S. ;

Price, Karen N. ;

Thuerlimann, Beat ;

Mouridsen, Henning ;

Mauriac, Louis ;

Forbes, John F. ;

Paridaens, Robert J. ;

Castiglione-Gertsch, Monica ;

Gelber, Richard D. ;

Colleoni, Marco ;

Lang, Istvan ;

Del Mastro, Lucia ;

Gladieff, Laurence ;

Rabaglio, Manuela ;

Smith, Ian E. ;

Chirgwin, Jacquie H. ;

Goldhirsch, Aron .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (12) :1972-1979

[7] Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen [J].

Dowsett, Mitch ;

Cuzick, Jack ;

Ingle, Jim ;

Coates, Alan ;

Forbes, John ;

Bliss, Judith ;

Buyse, Marc ;

Baum, Michael ;

Buzdar, Aman ;

Colleoni, Marco ;

Coombes, Charles ;

Snowdon, Claire ;

Gnant, Michael ;

Jakesz, Raimund ;

Kaufmann, Manfred ;

Boccardo, Francesco ;

Godwin, Jon ;

Davies, Christina ;

Peto, Richard .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (03) :509-518

[8] A Woman's Heart The Impact of Adjuvant Endocrine Therapy on Cardiovascular Health [J].

Ewer, Michael S. ;

Gluck, Stefan .

CANCER, 2009, 115 (09) :1813-1826

[9] Correcting for Discretionary Treatment Crossover in an Analysis of Survival in the Breast International Group BIG 1-98 Trial by Using the Inverse Probability of Censoring Weighted Method [J].

Finkelstein, Dianne M. ;

Schoenfeld, David A. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (09) :1093-1095

[10] Design, conduct, and analyses of Breast International Group (BIG) 1-98: A randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer [J].

Giobbie-Hurder, Anita ;

Price, Karen N. ;

Gelber, Richard D. .

CLINICAL TRIALS, 2009, 6 (03) :272-287

← 1 2 3 4 →